A study from the Northwestern Medicine Canning Thoracic Institute published on July 8 suggests that lung transplantation can significantly extend survival for certain patients with advanced, treatment-resistant non-small cell lung cancer confined to the lungs.
The research, featured in JAMA, examined outcomes for adults with end-stage pulmonary disease using data from the Double Lung Transplant Registry for Lung-Limited Malignancies (DREAM registry). Among 98 patients with stage IV lung cancer limited to the lungs, 17 received a double-lung transplant while 81 were treated with medical management alone. The study found that one-year survival was 100% among those who underwent transplantation compared to 41% among those who received only medical therapies. "This work changes what we can imagine for a highly selected group of patients who were previously considered beyond the reach of curative-intent intervention," said Ankit Bharat, MD, chief of thoracic surgery and director of the Canning Thoracic Institute. "We are not saying lung transplant is appropriate for every patient with stage IV lung cancer. We are saying that when the cancer is rigorously proven to be confined to the lungs...transplantation may offer a new path forward."
The DREAM program at Northwestern Medicine is currently believed to be unique in offering dedicated transplants for this patient population. Comprehensive staging techniques and surgical innovations have been implemented to reduce recurrence risk by ensuring no cancer cells remain or spread during surgery. Young Kwang Chae, MD, MPH, said, "In these rare select group of patients, DREAM provides us a disciplined, scientifically rigorous way to ask whether removing the organ containing all visible disease can change the natural history of an otherwise fatal condition." One-year post-transplant survival was also compared between recipients transplanted due to stage IV lung cancer and those transplanted for other causes; both groups had similar outcomes (100% vs 88%).
Patients like David Peterson from Washington DC and Laura Rotunno from Illinois shared their experiences as part of this research initiative after exhausting other treatment options. Peterson said, “When I first heard ‘lung transplant,’ I thought it was too extreme...but it became my second chance at life.” Rotunno reflected on her experience: “When I got the call that donor lungs were available, everything changed...Now I wake up every day thankful for simple things.”
During follow-up through January 2026, four out of seventeen transplant recipients experienced recurrence but received further therapy; two had died by study end. The authors emphasized longer-term follow-up will be necessary to assess durability and quality-of-life impacts after transplantation.
Northwestern Medicine has performed more than fifty such transplants since launching its program in 2014 as part of over seven hundred total procedures addressing various forms of end-stage pulmonary disease including COVID-19-related cases and cystic fibrosis. The health system operates under parent organization Northwestern Memorial HealthCare and engages in strategic collaborations focused on clinical research and education, according to the official website.
